Capitalized R&D in 3-Statement Models, Valuations, and Big Beautiful Bills

Why It Matters

Whether R&D is capitalized or expensed meaningfully alters profitability metrics and cash‑flow profiles, affecting valuations, comparability across peers, and investment decisions—especially as large tech firms increase AI spending with ambiguous accounting treatment.

Summary

The tutorial explains how capitalizing R&D shifts spending from operating expense to a capital asset on the balance sheet, with amortization flowing through the income statement and the cash outflow recorded as CapEx. The instructor demonstrates an amortization schedule (using a five-year, mid-year convention) and tax-era examples where U.S. rules temporarily required amortization, then changed after the 2025 legislative update. He cautions against routinely adjusting models to capitalize R&D because of practical forecasting challenges, judgment calls around useful lives and AI-related costs, and the extra work needed to make like-for-like comparisons. The video also shows how capitalized versus expensed R&D can materially distort EBITDA, ROIC, valuation multiples and DCF inputs.

Original Description

Learn more here: https://breakingintowallstreet.com/core-financial-modeling/?utm_medium=yt&utm_source=yt&utm_campaign=yt45

This tutorial presents several Excel examples and comparisons for companies that capitalize rather than expense R&D and explains the required adjustments, especially for valuation multiples.

Files & Resources:

https://breakingintowallstreet.com/kb/financial-statement-analysis/capitalized-rd/

Table of Contents:

0:00 Introduction

2:36 Part 1: The Short Answer

7:35 Part 2: What to Do for a Company Already Capitalizing R&D

11:14 Part 3: Comparability Issues and Valuation Multiples

14:42 Recap and Summary